EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel topical non-antibiotic antimicrobial products for the global eye care market, announces that President and CEO Ron Najafi, Ph.D., will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the St. Regis Hotel in New York City.
A live webcast and replay of the NovaBay presentation will be available on the company’s website at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, and CELLERX® for the aesthetic dermatology market, cleared by the FDA as a 510(k) medical device; and its AGANOCIDE® compounds, led by AURICLOSENE™.
NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel), Alpha Pharma LLC (Ukraine) and Ophthalmic Instrument Company in New Zealand.
In June 2015, NovaBay announced receipt of FDA-clearance for intelli-Case, a highly innovative, easy-to-use device for use with hydrogen peroxide disinfection solutions with soft and rigid gas permeable contact lenses.
Stay informed on NovaBay's progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website